A year ago, I didn't know a token from a prompt. Now I have an army of agents that help do day-to-day tasks, like publishing this newsletter. Where to start? Here is one option.
Become An AI Expert In Just 5 Minutes
If you’re a decision maker at your company, you need to be on the bleeding edge of, well, everything. But before you go signing up for seminars, conferences, lunch ‘n learns, and all that jazz, just know there’s a far better (and simpler) way: Subscribing to The Deep View.
This daily newsletter condenses everything you need to know about the latest and greatest AI developments into a 5-minute read. Squeeze it into your morning coffee break and before you know it, you’ll be an expert too.
Subscribe right here. It’s totally free, wildly informative, and trusted by 600,000+ readers at Google, Meta, Microsoft, and beyond.

Help shape MBS Digest: a 3-minute reader survey
We'd like to know who reads the Digest and what would make it more useful to you. The survey takes about three minutes. Answers are reported only in totals, never by name, and we'll share what we learn in a future issue.
Vol. 2, Issue 19 | November 17, 2026
Validation of clinical and preclinical obesity across four global cohorts leads this issue, followed by surgery after incretin therapy and FDA's new eye-safety warning for GLP-1 drugs. Sleeve-leak drainage, semaglutide in HFpEF and lean-mass loss after surgery round out the research.

Article of the Week
Across global cohorts, clinical obesity carries a mortality hazard ratio of 1.69
An Pan, Shengping Yang, Rafael Ramos et al. | Nature, Nov. 11, 2026 | 10.1038/s41586-026-11237-5
Suggested by Phil Schauer
An observational analysis of four cohorts included 844,108 adults and combined anthropometry with organ-function criteria to classify obesity. Mortality analyses used three cohorts with median follow-up of 11.2–15.3 years. Compared with people without defined obesity or organ dysfunction, pooled mortality hazard ratios were 1.69 (95% CI 1.64–1.73) for clinical obesity and 1.19 (1.14–1.24) for preclinical obesity. Both estimates use the same reference group.
After population-level attributable-fraction adjustment, clinical obesity represented 22.7%–31.3% of those meeting the combined adiposity definition. This approach statistically separates excess adiposity from organ dysfunction, rather than treating every coexisting condition as caused by obesity. Variable retrospective ascertainment limits individual diagnostic interpretation. The study had no industry funding, although several coauthors disclosed industry relationships.

KEY FINDING
Hazard ratios of 1.69 and 1.19 distinguish mortality associations for clinical and preclinical obesity against a common reference. The analysis supports risk differentiation, not treatment exclusion based on a category alone.
Coming Thursday — Editorial
Francesco Rubino, MD, on why clinical and preclinical obesity matter
MBS Digest editorial | Thursday, November 19, 2026
Disclosure: Dr. Rubino is a coauthor of the Nature study featured above as this week’s Article of the Week (doi:10.1038/s41586-026-11237-5).
On Thursday, MBS Digest will publish an editorial by Francesco Rubino, MD, Professor of Metabolic and Bariatric Surgery at King’s College London, who chaired the 2025 Lancet Commission on clinical obesity. It is the Digest’s first editorial from an author outside the editorial board. The editorial considers what the study’s results in 844,108 adults across four countries mean for patients, clinicians, health services and metabolic surgery. The board's voting editors approved the editorial for publication.
Research and Regulatory Items (Sections A, B and D)
Surgery strategy yields estimated 28.2% weight loss after initial incretin therapy
Hamlet Gasoyan, Christopher B. Boyer, Rebecca Isakoff et al. | eClinicalMedicine, Nov. 2026 | 10.1016/j.eclinm.2026.104321
Suggested by John D. Scott, MD
A Cleveland Clinic target-trial emulation included 20,486 adults initially taking semaglutide or tirzepatide at routine-care doses. Per-protocol weight loss at two years after trial entry was 28.2% with surgery versus 10.9% with continued original medication. Estimates were 16.0% after switching between the two drugs, 8.2% with another medication, and 4.0% after stopping. Weight change began at the initial prescription fill, not at surgery.
The surgical estimate had a 95% CI of 19.6%–36.8%, versus 9.1%–13.1% for continuing the original drug. These estimates describe sustained treatment strategies after at least 90 days of initial therapy, rather than randomized drug-versus-surgery assignment. Residual treatment-selection confounding limits causal interpretation despite weighting. Cleveland Clinic funded the study; disclosed relationships include a coauthor's employment at Novo Nordisk.
KEY FINDING
The surgical pathway was associated with an estimated 28.2% weight loss, compared with 10.9% with continued original medication. The measurement includes weight change during initial incretin treatment.
FDA adds a GLP-1 class warning for rare ischemic optic neuropathy
U.S. Food and Drug Administration | FDA Drug Safety Communication, Nov. 9, 2026 | Source ↗
FDA's November 9 communication requires a NAION warning in the Warnings and Precautions section for GLP-1 receptor agonists, including tirzepatide. Its meta-analysis covered 126 randomized trials and 134,253 participants. Probable non-arteritic anterior ischemic optic neuropathy occurred in 10 treated participants versus 5 comparators. Incidence was 6.4 versus 3.8 cases per 100,000 person-years, respectively.
In Sentinel data, the hazard ratio was 1.43 versus DPP4 inhibitors (95% CI 1.02–2.01) and 1.19 versus SGLT2 inhibitors (0.91–1.54). The signal supports a precaution, but sparse trial events and overlapping baseline risk factors leave causality uncertain. FDA recommends prompt ophthalmology assessment for suspected NAION and considering discontinuation after an event unless benefits clearly outweigh risk. This is not a boxed warning.
CONTEXT
6.4 versus 3.8 cases per 100,000 person-years places the trial signal in absolute-risk terms. FDA's class-wide labeling change concerns a rare event with potentially permanent vision loss.
This announcement is not a paid advertisement. It is for informational purposes only and does not constitute an endorsement of the ASMBS. Likewise, the ASMBS has approved the use of its logo on the condition it is not associated as an endorsement of the MBS-Digest.
Semaglutide lowers exercise wedge pressure by 10.6 mmHg versus placebo in HFpEF
Barry A. Borlaug, Michael D. Jensen, Milton Packer et al. | Nature Medicine, Nov. 8, 2026 | 10.1038/s41591-026-04762-3
Suggested by Donna H. Ryan, MD
In a randomized, double-blind trial, 81 adults with obesity and HFpEF received semaglutide 2.4 mg weekly or placebo for 52 weeks. Exercise pulmonary artery wedge pressure fell 9.8 mmHg with semaglutide and rose 0.9 mmHg with placebo. The estimated between-group difference was −10.6 mmHg (95% CI −13.3 to −8.0). Invasive pressure measurement provides evidence of reduced cardiac congestion beyond a change in symptoms alone.
Hemodynamic remission, defined by normal pressures at rest and exercise, occurred in 53.7% versus 7.4%; resting pressure also favored semaglutide by 7.1 mmHg. The findings do not isolate a direct myocardial effect independent of weight loss. Government funding supported the trial, and Novo Nordisk provided the drug and placebo. Borlaug disclosed industry research and consulting relationships, including Novo Nordisk.
KEY FINDING
A 10.6-mmHg treatment difference in exercise filling pressure provides randomized evidence of reduced congestion. Hemodynamic remission was more common with semaglutide than placebo at 52 weeks.
A 30-study review separates absolute from proportional lean-mass loss
Jorge Urbina, John Scott, Manuel Rodrigo Prieto Aldape et al. | Obesity Surgery, Nov. 13, 2026 | 10.1007/s11695-026-09024-2
Disclosure: Production Editor John D. Scott is a coauthor and was nonvoting, with read-only ballot access.
Urbina and colleagues reviewed 31 studies and pooled 30, comprising 5,616 participants, with 12 months as the primary assessment. They analyzed DXA and bioelectrical impedance measurements separately. Surgery was associated with larger reductions in weight, fat mass, and absolute lean mass than GLP-1-based therapy. The larger lean-mass reduction was accompanied by greater overall weight loss, without worse proportional preservation.
Absolute kilograms lost and the proportion of weight loss attributable to lean tissue answer different questions. Relative fat-mass changes also varied with the measurement method, making the separate DXA and impedance analyses important. Indirect comparisons with substantial heterogeneity cannot establish a head-to-head treatment effect. Authors disclosed consulting or proctoring relationships with drug and device manufacturers.
KEY FINDING
The 30-study synthesis found greater absolute lean-mass loss alongside greater total weight loss after surgery. That result does not establish poorer proportional lean-mass preservation.

GLP-1RA discontinuation is associated with twice the event rate in type 2 diabetes
Antonio Ceriello, Francesco Prattichizzo, Giuseppe Lucisano et al. | The Lancet Regional Health – Europe, Nov. 9, 2026 | 10.1016/j.lanepe.2026.101881
Suggested by John D. Scott, MD
An Italian retrospective study analyzed 80,302 GLP-1RA initiators with type 2 diabetes and no previous major cardiovascular event. Matching yielded 28,713 patients in each treatment-persistence group. After discontinuation, the composite rate of nonfatal MI, nonfatal stroke, or all-cause death was 3.94 versus 1.96 per 100 person-years with persistence. The corresponding hazard ratio was 2.03 (95% CI 1.92–2.14).
All-cause mortality rates were 2.23 versus 0.48 per 100 person-years, with a hazard ratio of 4.81 (95% CI 4.39–5.26). The authors judge this unusually large association unlikely to reflect withdrawal alone. Unmeasured reasons for stopping, including worsening health, leave substantial scope for reverse causality. Italian public funding supported the work in part; several authors disclosed industry relationships.
KEY FINDING
3.94 versus 1.96 events per 100 person-years links discontinuation to a higher subsequent event rate. The composite includes all-cause death, not cardiovascular death alone.
GLP-1RA cancer associations depend on the active comparator
Jesús Gibran Hernández-Pérez, Omer Abdelgadir, Luisa Torres-Sánchez et al. | JAMA Network Open, Nov. 3, 2026 | 10.1001/jamanetworkopen.2026.41869
Suggested by John D. Scott, MD
Five single-system target-trial emulations compared GLP-1RA initiation with other therapies in type 2 diabetes. The insulin comparison included 13,649 GLP-1RA users and 16,750 insulin users. Estimated three-year obesity-related cancer risk was 2.01% versus 3.26%, respectively, with a hazard ratio of 0.62 (95% CI 0.49–0.77). Against sulfonylureas, estimated risks were 2.85% versus 3.98%, with a hazard ratio of 0.67 (0.54–0.84).
Comparisons with metformin, SGLT2 inhibitors, and DPP4 inhibitors did not show clear overall differences. In high-severity diabetes, the three-year risk difference versus SGLT2 inhibitors was +1.61 percentage points (95% CI 0.17–2.89), favoring the comparator. Residual treatment-selection confounding limits any inference about cancer prevention. Public and nonprofit grants supported the work; one coauthor disclosed pharmaceutical consulting fees.
KEY FINDING
2.01% versus 3.26% estimated three-year cancer risk favored GLP-1RAs over insulin. The absence of a consistent advantage across comparators argues against a class-wide cancer-prevention conclusion.
Clinical obesity criteria identify 73.8% of 2,316 surgical patients
Simone Cremona, Ricardo V. Cohen, Francois Pattou et al. | JAMA Network Open, Aug. 11, 2026 | 10.1001/jamanetworkopen.2026.28395
Suggested by John D. Scott, MD
A retrospective audit classified 2,316 adults undergoing primary bypass or sleeve gastrectomy at four international centers. Clinical obesity accounted for 1,709 patients (73.8%), versus 607 (26.2%) with preclinical obesity. BMI distributions were similar despite differences in disease burden. In the French cohort, 30-day major complications occurred in 4.0% versus 1.1%, respectively; the analyses compared groups within each center.
The classification distinguished existing organ dysfunction within a population already selected for surgery, rather than separating patients by BMI alone. Clinical obesity prevalence ranged from 62.7% in Brazil to 79.3% in the UK. Pragmatic proxies for organ dysfunction could overattribute disease to adiposity and inflate prevalence. Several authors disclosed relationships with drug and device manufacturers outside this work.
KEY FINDING
73.8% met clinical-obesity criteria, while roughly one quarter had preclinical obesity despite similar BMI distributions. The distinction describes disease burden within surgical practice, not a tested rule for denying surgery.
Pigtail drainage resolves 80.0% of late versus 52.4% of early sleeve leaks
Saeed Safari, Mohammad Moradi, Erfan Abdiaei et al. | Obesity Surgery, Nov. 11, 2026 | 10.1007/s11695-026-09028-y
A retrospective referral-center cohort included 50 sleeve leaks: 26 presenting before day 7 and 24 on or after day 7. We attempted double pigtail stent placement in 41 patients as part of multidisciplinary treatment. Resolution after pigtail drainage was 80.0% for late versus 52.4% for early leaks (P=0.031). The primary outcome was closure without definitive reconstructive surgery, rather than stent placement alone.
Early leaks required radiologic drainage in 84.6% versus 54.2% of cases and surgical intervention in 80.8% versus 25.0%. Definitive reconstruction was also more frequent, at 53.8% versus 25.0%. This pattern links early presentation to a more intervention-intensive course, even when endoscopic drainage is available. Treatment selection in a retrospective referral cohort prevents attribution of the timing difference to stent efficacy alone.
KEY FINDING
80.0% resolution in late leaks supports internal drainage as a useful component of sleeve-leak care. Early leaks more often required radiologic drainage and surgery in this series.
Closing the gaps in knowledge...
Production Editor John D. Scott MD FACS | [email protected]
This issue's ballot: 7 of 12 board seats voted.
Metabolic and Bariatric Sciences Digest | November 17, 2026 | Vol. 2, Issue 19
For educational purposes only.



